辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

休市中 12-08 16:00:00 EST

28.78

+0.15

+0.52%

盘后28.77

-0.01-0.03%

19:59 EST

最高28.97	最低28.59	成交量3,189万
今开28.65	昨收28.63	日振幅1.31%
总市值1,625亿	流通市值1,624亿	总股本56.46亿
成交额9.17亿	换手率0.57%	流通股本56.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":28.78,"timestamp":1702069200000,"preClose":28.63,"halted":0,"volume":31890740,"hourTrading":{"tag":"盘后","latestPrice":28.77,"preClose":28.78,"latestTime":"19:59 EST","volume":1318252,"amount":37938698.591154,"timestamp":1702083586498},"delay":0,"floatShares":5641472115,"shares":5646413292,"eps":1.835898,"marketStatus":"休市中","marketStatusCode":7,"change":0.15,"latestTime":"12-08 16:00:00 EST","open":28.65,"high":28.965,"low":28.59,"amount":917426749.0794001,"amplitude":0.013098,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.835898,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1702285200000},"adr":0,"listingDate":-819144000000,"adjPreClose":28.63,"adrRate":0,"dividendRate":0.056637,"preHourTrading":{"tag":"盘前","latestPrice":28.66,"preClose":28.63,"latestTime":"09:29 EST","volume":152513,"amount":4371525.262848,"timestamp":1702045799999},"postHourTrading":{"tag":"盘后","latestPrice":28.77,"preClose":28.78,"latestTime":"19:59 EST","volume":1318252,"amount":37938698.591154,"timestamp":1702083586498},"volumeRatio":0.6130866116602322,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1708059600000,"strike":"26.0","timestamp":1702049242681,"price":0.41999998688697815,"volume":5000,"amount":210000,"type":"-"},{"symbol":"PFE","call":false,"expireDate":1705640400000,"strike":"40.0","timestamp":1702064632606,"price":11.149999618530273,"volume":2590,"amount":2887850,"type":"-"}]}},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"2389107617","title":"分析师称，艾伯维斥资 87 亿美元押注 Cerevel 风险很大，但很明智","url":"https://stock-news.laohu8.com/highlight/detail?id=2389107617","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389107617?lang=zh_cn&edition=full","pubTime":"2023-12-08 02:30","pubTimestamp":1701973829,"startTime":"0","endTime":"0","summary":"总部位于伊利诺伊州北芝加哥的艾伯维公司周三晚些时候说 ，它将以 87 亿美元的价格收购 Cerevel，从而获得一系列正在测试的治疗神经系统疾病的药物组合，其中包括治疗精神分裂症的 emraclidine。分析师说，Cerevel 公司仍在进行 emraclidine 的中期试验，这意味着这笔交易并没有 \"去风险\"，因为该疗法可能会在试验中失败。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389075310","title":"贝恩以 87 亿美元出售 Cerevel，获得超过十倍的回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2389075310","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389075310?lang=zh_cn&edition=full","pubTime":"2023-12-08 01:35","pubTimestamp":1701970536,"startTime":"0","endTime":"0","summary":"Greg Roumeliotis    路透12月7日 - 据监管文件显示，私募股权公司贝恩资本在Cerevel Therapeutics Holdings Inc   以87亿美元的价格出售给艾伯维公司后，将获得超过其投资额2.5亿美元的10倍。贝恩的成功反映了其对 Cerevel 药物组合的高风险押注。贝恩和辉瑞公司保留了 Cerevel 公司 15% 的股份，并通过与特殊目的收购工具合并，于 2020 年将公司上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389025404","title":"“AI+机器人”18C第一股，一窥晶泰科技的价值进阶之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2389025404","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2389025404?lang=zh_cn&edition=full","pubTime":"2023-12-07 21:11","pubTimestamp":1701954699,"startTime":"0","endTime":"0","summary":"晶泰科技递表港交所","market":"us","thumbnail":"https://img7.gelonghui.com/column/8.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/8.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/671712","is_publish_highlight":false},{"id":"2389061620","title":"更新版 1-艾伯维将以 87 亿美元收购药物开发商 Cerevel","url":"https://stock-news.laohu8.com/highlight/detail?id=2389061620","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389061620?lang=zh_cn&edition=full","pubTime":"2023-12-07 05:42","pubTimestamp":1701898927,"startTime":"0","endTime":"0","summary":"    路透12月6日 - 艾伯维  周三表示，将以总价值约87亿美元的股权收购Cerevel Therapeutics  。艾伯维将以每股 45 美元的现金收购 Cerevel 的所有流通股，比周三收盘价溢价 22%。该公司正在进行临床试验的主要药物之一 Emraclidine 主要针对精神分裂症患者。这家总部位于马萨诸塞州剑桥市的公司成立于2018年，当时辉瑞公司  在贝恩3.5亿美元投资的支持下，将其开发中枢神经系统药物的部门独立出来。Cerevel 于 2020 年在纽约股票交易所上市，贝恩和辉瑞分别持股约 36% 和 15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389806605","title":"辉瑞下跌1.24%，报28.73美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2389806605","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389806605?lang=zh_cn&edition=full","pubTime":"2023-12-07 04:53","pubTimestamp":1701896025,"startTime":"0","endTime":"0","summary":"12月7日，辉瑞(PFE)盘中下跌1.24%，截至04:53，报28.73美元/股，成交7.69亿美元。财务数据显示，截至2023年10月01日，辉瑞收入总额442.47亿美元，同比减少41.81%；归母净利润54.88亿美元，同比减少79.19%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/07045338692556.shtml","is_publish_highlight":false},{"id":"2389729457","title":"当心，如日中天的科技“七巨头”越来越像“漂亮50”","url":"https://stock-news.laohu8.com/highlight/detail?id=2389729457","media":"巴伦周刊","top":-1,"share":"https://www.laohu8.com/m/news/2389729457?lang=zh_cn&edition=full","pubTime":"2023-12-06 07:58","pubTimestamp":1701820712,"startTime":"0","endTime":"0","summary":"今天的美股科技“七巨头”和20世纪70年代初的“漂亮50”有什么共同之处？阿波罗全球管理公司策略师斯托斯滕·斯洛克近日指出，“七巨头”和“漂亮50”除了都代表了美国股市集中度的极端水平，市盈率也具有可比性。正因为如此，许多华尔街人士一致认为“七巨头”的市盈率高于标普500指数是合理的。“漂亮50”还有几份被纳入公司略有不同的名单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://tech.ifeng.com/c/8VHsdPcbms8","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8VHsdPcbms8","is_publish_highlight":false},{"id":"2389721411","title":"更新版 1-更新 3-礼来肥胖症药物现已在美国药房上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2389721411","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389721411?lang=zh_cn&edition=full","pubTime":"2023-12-06 01:10","pubTimestamp":1701796259,"startTime":"0","endTime":"0","summary":" Patrick  Wingrove/Manas Mishra    路透12月5日 - 礼来  周二表示，其最近获批的肥胖症治疗药物Zepbound现已在美国药房上市，医保不包括该药物的客户每月可支付550美元，即上市价格的一半。礼来公司表示，其商业储蓄卡计划现已在连锁药店推出。当美国食品和药物管理局于 11 月批准 Zepbound  时，礼来公司表示它将在美国感恩节假期后上市。礼来的肥胖症药物与之前获批的糖尿病药物 Mounjaro 的活性成分 tirzepatide 相同，后者自 2022 年上市以来一直被用于标签外减肥。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389874008","title":"当心：科技“七巨头”，越来越像“漂亮50”","url":"https://stock-news.laohu8.com/highlight/detail?id=2389874008","media":"巴伦周刊","top":-1,"share":"https://www.laohu8.com/m/news/2389874008?lang=zh_cn&edition=full","pubTime":"2023-12-05 22:14","pubTimestamp":1701785643,"startTime":"0","endTime":"0","summary":"崩盘曾提高了投资者对估值过高股票的警惕，但他们显然已经忘了历史教训","market":"hk","thumbnail":"https://img.huxiucdn.com/article/cover/202312/05/220312897608.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202312/05/220312897608.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/2387232.html","is_publish_highlight":false},{"id":"2389579619","title":"辉瑞(PFE.US)、Valneva(VALN.US)完成莱姆病疫苗3期试验招募","url":"https://stock-news.laohu8.com/highlight/detail?id=2389579619","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2389579619?lang=zh_cn&edition=full","pubTime":"2023-12-05 11:29","pubTimestamp":1701746991,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞(PFE.US)及其合作伙伴Valneva(VALN.US)表示，他们已经完成了莱姆病候选疫苗VLA15的3期试验招募，辉瑞计划于2026年在美国和欧洲申请该产品的监管批准。这项3期试验在美国、加拿大和欧洲莱姆病流行地区招募了9437名年龄在5岁及以上的参与者。这项研究预计将于2025年底结束。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1033453.html","is_publish_highlight":false},{"id":"2388731545","title":"背景资料-罗氏斥资 27 亿美元收购 Carmot 公司，加入肥胖症药物竞争行列","url":"https://stock-news.laohu8.com/highlight/detail?id=2388731545","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2388731545?lang=zh_cn&edition=full","pubTime":"2023-12-04 20:53","pubTimestamp":1701694424,"startTime":"0","endTime":"0","summary":"罗氏与卡莫特治疗公司     罗氏公司以 27 亿美元收购了 Carmot Therapeutics 公司，并将 CT-388 作为收购的一部分。Carmot公司的每周一次注射剂与礼来公司  的Mounjaro或Zepbound属于同一类药物。罗氏表示，新收购的候选药物已完成早期试验，准备在三个试验阶段中的第二个阶段进行人体试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2388739394","title":"减肥神药“冷暖不一”：罗氏31亿美元重金布局，辉瑞再次放弃在研产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2388739394","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2388739394?lang=zh_cn&edition=full","pubTime":"2023-12-04 20:24","pubTimestamp":1701692669,"startTime":"0","endTime":"0","summary":"当地时间12月4日，知名跨国药企罗氏宣布，已签订最终收购协议，收购总部位于美国的公司Carmot。根据协议，罗氏将向Carmot支付27亿美元的预付款以及4亿美元的额外里程碑付款。不过，这次总额高达31亿美元的收购案最受外界关注的是，罗氏将获得多款GLP-1产品，这意味着罗氏正式入局今年以来在全球大火的GLP-1赛道。辉瑞口服减肥药存在一些患者无法忍受的副作用这已经是辉瑞第二次放弃GLP-1在研产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120420250083cf5022&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120420250083cf5022&s=b","is_publish_highlight":false},{"id":"2388787305","title":"AI选股！三支“超越标普”策略的成分股 集体遭低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2388787305","media":"英为财情Invest...","top":-1,"share":"https://www.laohu8.com/m/news/2388787305?lang=zh_cn&edition=full","pubTime":"2023-12-04 17:47","pubTimestamp":1701683220,"startTime":"0","endTime":"0","summary":"人工智能，不仅仅是聊聊天，画幅画，世界各地的金融机构和大佬投资者也都用上了AI，他们使用、定制和开发人工智能，以提高投资回报，最大限度地减少损失。现在，普通投资者也有机会使用AI辅助投资决策了，InvestingPro的用户可以在舒适的家中使用全新的旗舰人工智能选股工具——ProPicks来帮助研究股票。ProPicks结合了50多...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/Oxy1cqDJDLQsAspVe6IqojjcwS_tn2-_-QOIJVRKYxrssAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Oxy1cqDJDLQsAspVe6IqojjcwS_tn2-_-QOIJVRKYxrssAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20231204A07AF600","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20231204A07AF600","is_publish_highlight":false},{"id":"2388520092","title":"败绩接二连三，小分子GLP-1的理想与现实","url":"https://stock-news.laohu8.com/highlight/detail?id=2388520092","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2388520092?lang=zh_cn&edition=full","pubTime":"2023-12-04 14:37","pubTimestamp":1701671846,"startTime":"0","endTime":"0","summary":"也正因此，部分药企积极布局小分子GLP-1。辉瑞映射的现实在小分子GLP-1领域，辉瑞接连遭遇败战。在这场小分子GLP-1的竞争中，礼来已经领先。礼来的小分子GLP-1受体激动剂orforglipron，目前正在进行3期的肥胖症研究。11月9日，阿斯利康就以最高交易金额超过20亿美元的价格引进了一款小分子GLP-1 ECC5004。毕竟，辉瑞遭遇的问题，属于小分子GLP-1开发的共性问题，而不只是辉瑞自身的技术问题。很显然，在这场小分子GLP-1的大战中，竞赛才刚刚开始。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120414405383ce2442&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120414405383ce2442&s=b","is_publish_highlight":false},{"id":"2388270361","title":"道指上周五涨0.82% 阿里跌1.2%辉瑞跌5.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2388270361","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2388270361?lang=zh_cn&edition=full","pubTime":"2023-12-04 09:35","pubTimestamp":1701653700,"startTime":"0","endTime":"0","summary":"　　美国大型科技股多数下跌，苹果涨0.68%，英伟达跌0.01%，亚马逊涨0.64%，谷歌跌0.45%，脸书跌0.71%，微软跌1.16%，奈飞跌1.74%，特斯拉跌0.52%，英特尔跌2.15%，辉瑞跌5.12%。热门中概股多数下跌，新东方涨0.31%，拼多多跌1.47%，爱奇艺跌2.00%，阿里巴巴跌1.19%，京东跌0.98%，百度跌1.59%，哔哩哔哩涨1.59%，小鹏汽车跌5.24%，理想汽车跌1.76%，蔚来跌1.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2023-12-04/doc-imzwvfna8189877.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2023-12-04/doc-imzwvfna8189877.shtml","is_publish_highlight":false},{"id":"2388382262","title":"鲍威尔重磅发声！","url":"https://stock-news.laohu8.com/highlight/detail?id=2388382262","media":"中国基金报","top":-1,"share":"https://www.laohu8.com/m/news/2388382262?lang=zh_cn&edition=full","pubTime":"2023-12-02 07:57","pubTimestamp":1701475044,"startTime":"0","endTime":"0","summary":"美联储主席鲍威尔发声，继续给市场降息预期“泼冷水”。鲍威尔重磅发声：宣布战胜通胀还为时过早根据香港万得通讯社，当地时间12月1日周五，美联储主席鲍威尔在亚特兰大Spelman College参加对话活动时重申，如果时机合适，我们准备进一步收紧政策。鲍威尔补充道，美联储采取的强有力的行动已经使政策利率进入了限制性区间，这意味着紧缩的货币政策正在给经济活动和通货膨胀带来下行压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120207584783c69d40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120207584783c69d40&s=b","is_publish_highlight":false},{"id":"2388264897","title":"隔夜美股全复盘(12.2)| 三大股指低开高走，悉数收涨；戴尔跌超5%，Q3营收同比下降10%，低于预期，Q4指引低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2388264897","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2388264897?lang=zh_cn&edition=full","pubTime":"2023-12-02 07:09","pubTimestamp":1701472175,"startTime":"0","endTime":"0","summary":"三大股指低开高走，悉数收涨；戴尔跌超5%，Q3营收同比下降10%，低于预期，Q4指引低于预期","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/669890","is_publish_highlight":false},{"id":"2388598982","title":"再折戟！辉瑞终止推进小分子GLP-1R激动剂III期开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2388598982","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2388598982?lang=zh_cn&edition=full","pubTime":"2023-12-02 00:02","pubTimestamp":1701446538,"startTime":"0","endTime":"0","summary":"12月1日，辉瑞公布了口服小分子胰高血糖素样肽-1受体激动剂Danuglipron用于成人肥胖患者的IIb期临床试验的数据。不过辉瑞表示，不计划将这款每日口服两次的药物推进至III期临床阶段。不过在礼来和诺和诺德两大霸主开发的多肽类药物已经在开展如火如荼的市场争夺赛的情况下，辉瑞则试图通过布局小分子GLP-1R类药物潜入这一赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312020010568222e077&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312020010568222e077&s=b","is_publish_highlight":false},{"id":"2388256956","title":"BUZZ-辉瑞放弃推进每日两次肥胖药研究的计划后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2388256956","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2388256956?lang=zh_cn&edition=full","pubTime":"2023-12-01 23:43","pubTimestamp":1701445394,"startTime":"0","endTime":"0","summary":"** PFE 公司表示，它将把重点放在每日一次的改良释放版丹格列净上，预计明年将获得该药物在人体中的反应数据。** 辉瑞公司表示，虽然在这项研究中没有观察到新的安全性信号，但试验中高达73%的患者有恶心症状，高达47%的患者有呕吐症状，高达25%的患者有腹泻症状。** 包括本交易日的跌幅在内，辉瑞制药今年累计下跌约 44","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2388258259","title":"美股异动 | 放弃减肥药danuglipron研发 辉瑞(PFE.US)跌超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2388258259","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2388258259?lang=zh_cn&edition=full","pubTime":"2023-12-01 22:33","pubTimestamp":1701441202,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，辉瑞(PFE.US)股价走低，截至发稿，该股跌超6%，报28.54美元。辉瑞公司宣布，计划放弃其实验性减肥药danuglipron(每日口服两次)的研发。该公司称，观察到患者的不良反应发生率很高，虽然这些副作用大多是轻微的和胃肠道方面的。在临床试验中，相当一部分患者因无法忍受副作用(例如恶心和呕吐)停止了服用danuglipron。因此，每日服用两次的danuglipron将不会进入三期临床试验。但辉瑞公司表示，它仍计划在2024年上半年公布danuglipron每日一次的二期试验数据，这将为未来的方向提供信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1032572.html","is_publish_highlight":false},{"id":"2388725880","title":"辉瑞盘中异动 早盘股价大跌5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2388725880","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2388725880?lang=zh_cn&edition=full","pubTime":"2023-12-01 22:31","pubTimestamp":1701441089,"startTime":"0","endTime":"0","summary":"北京时间2023年12月01日22时31分，辉瑞股票出现异动，股价大幅下挫5.64%。辉瑞股票所在的制药行业中，整体涨幅为0.38%。辉瑞在全球销售这些产品，国际销售额占其总销售额的近 50%。消息层面，截至22时31分，辉瑞股票正面舆情新闻比例9.09%。这一消息随后也得到了辉瑞的证实，引发行业关注。自2023年以来，3M公司已在全球范围内进行了两次大规模裁员。整体合计，3M公司目前约裁员共计8500人，占其全球员工总数的10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120122313083c51aa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120122313083c51aa3&s=b","is_publish_highlight":false}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":-0.0045},{"period":"1month","weight":-0.0662},{"period":"3month","weight":-0.1597},{"period":"6month","weight":-0.2615},{"period":"1year","weight":-0.4442},{"period":"ytd","weight":-0.4383}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0525},{"period":"3month","weight":0.033},{"period":"6month","weight":0.0705},{"period":"1year","weight":0.1614},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.465116,"avgChangeRate":0.002671},{"month":2,"riseRate":0.465116,"avgChangeRate":-0.006887},{"month":3,"riseRate":0.604651,"avgChangeRate":0.015315},{"month":4,"riseRate":0.613636,"avgChangeRate":0.021662},{"month":5,"riseRate":0.5,"avgChangeRate":0.00626},{"month":6,"riseRate":0.5,"avgChangeRate":0.002739},{"month":7,"riseRate":0.477273,"avgChangeRate":0.010684},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000087},{"month":9,"riseRate":0.454545,"avgChangeRate":0.004027},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.009292}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.19.1","shortVersion":"4.19.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}